Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gaviscon is a widely used over-the-counter medication for the treatment of gastroesophageal reflux disease (GERD), heartburn, and acid indigestion. Its primary mechanism of action distinguishes it from simple antacids; it contains an alginate (typically sodium alginate) which, upon contact with gastric acid, precipitates into a viscous, pH-neutral gel. This gel, often called a "raft," floats on top of the stomach contents, creating a physical barrier that prevents the reflux of acid and pepsin into the esophagus. Most formulations also include antacids like sodium bicarbonate or calcium carbonate, which neutralize existing stomach acid and provide carbon dioxide bubbles that help the alginate raft float. While the specific active ingredients can vary by region—with the UK version emphasizing the alginate raft and some US versions utilizing aluminum hydroxide and magnesium carbonate—the brand is synonymous with rapid symptomatic relief of reflux symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gaviscon.